1. Race against time
====================

1.1. Artesunate---dapsone---proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response.
----------------------------------------------------------------------------------------------------------------------

The antifolate combination sulphadoxine--pyrimethamine (SP) has been the drug usually deployed to replace chloroquine when it begins to fail in malaria treatment programmes. Resistance by *Plasmodium falciparum* to antifolate combinations emerges more rapidly than against quinoline antimalarials however, and SP failure is becoming increasingly common. SP treatment failures appear attributable to point mutations in genes coding parasite dihydrofolate reductase (*dhfr*) and dihydropteroyl synthetase (*dhps*). High level SP resistance is prevalent in Southeast Asia and South America, and is attributed to the I164L mutation of the *dhfr* gene. In Thailand I164L prevalence was recently assessed as 25%.

The antifolate combination known as Lap-Dap comprises two well known agents, chlorproguanil and dapsone, and is under development to replace SP. Lap-Dap exhibits greater antimalarial potency than SP, and is more rapidly eliminated; the latter fact is thought likely to decrease the emergence of resistance.

In the study reported, 50 patients suffering uncomplicated falciparum malaria were admitted and treated with the following combination: artesunate (4 mg/Kg), dapsone (2.5 mg/Kg) and proguanil (8 mg/Kg); proguanil is an antifolate exhibiting very similar pharmacodynamics and pharmacokinetic properties to chlorproguanil. Subjects were monitored daily and followed for 28 days in a non-malarious area. Treatment outcomes were reported in line with standard WHO definitions.

Blood samples were collected on admission for *dhfr* and *dhps* genotyping, and on recrudescence when such occurred. Of importance, the PCR primers used in the genotyping analysis were specific for *P. falciparum*. In cases where the admission and recrudescence enzyme genotypes differed, further genotypic analysis of the parasite was undertaken (for MSP~1~, MSP~2~, and GLURP). Potential association between treatment outcome and parasite genotype was tested by means of *χ* ^2^ and Fisher\'s exact tests.

Of the 50 subjects, two discharged themselves prematurely for reasons unrelated to the study; mean patient age was 27 years (range 18--56), and mean weight 53.0 Kg (SD=8.1); 41/50 subjects were male. Treatments were well tolerated with no serious adverse events reported. Median admission haematocrit was 36% (range 18--49%), dropping to 33% (range 22--45%) on day 7, and recovering to 38% (range 29--49%) by day 28. No subject developed severe anaemia or haemoglobinuria. Median fever and parasite clearance times were 22 (range 4--124) and 40 (range 21--71) hours, respectively. No significant differences in age or admission parasitaemia were observed when analyzed by clinical outcome.

Genotyping revealed 69% (33/48) of parasites to be carrying quadruple *dhfr* mutations. The I164L mutation, which confers high level resistance, was present in 77% (37/48) of isolates. Nearly all (47/48) of isolates carried *dhps* mutations at residue 436; mutations at residues 436, 540, and 581 were found in 29, 87, and 77%, respectively; 67% (32/48) carried quadruple *dhps* mutations.

Subjects carrying triple or quadruple *dhfr* mutations exhibited treatment failure rates of 4% (2/48) and 19% (9/48) respectively. Overall, subjects carrying an I164L mutation exhibited a 70% (26/37) cure rate. Interestingly, *dhps* mutations did not appear to affect treatment outcome.

Comparison of admission and recrudescence genotypes was possible in 10/11 treatment failures: 7/10 exhibited identical admission and recrudescence phenotypes; 2/10 showed evidence of dual strain infection; 1/10 showed evidence of spontaneous in vivo *dhps* mutation.

The authors conclude that the overall 28 day treatment failure rate of 21% they report is not adequate to recommend general deployment, and that the major determinant of failure is the presence of the I164L *dhfr* mutation. The authors worry that by the time the very similar artesunate-dapsone-chlorproguanil (artesunate-Lap-dap, or 'ADC') has completed development, its deployment will have been frustrated by spread of the I164L mutation in Africa.

*Trans R Soc Trop Med Hyg. 2004; 99: 142--149*

2. Antimalarials for SARS?
==========================

2.1. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
----------------------------------------------------------------------------------------

The emergence of severe acute respiratory syndrome (SARS) in Guangdong, China, and its subsequent global spread, were events of major significance. A novel coronavirus, dubbed SARS-CoV, was identified as the responsible microorganism of SARS; four other coronaviruses are known to cause upper respiratory tract infections in man, particularly during winter months when they may account for one third of "common colds".

When SARS struck in 2003, no effective specific treatment was known, although it has been suggested that the antiviral ribavirin in combination with a protease inhibitor such as ritonavir and lopinavir may have ant-SARS activity. Compounds reported as showing activity against SARS-CoV include the liquorice root extract glycyrrhizin, the anthelminthic niclosamide, a nitric oxide inhibitor called 'SNAP', and another protease inhibitor, nelfinavir. Additionally, immune mediated lung damage during the course of infection with SARS may be open to therapy, possibly with interferon and systemic steroids.

Chloroquine is known to possess activity against a number of viruses, including HIV-1, hepatitis B, herpes simplex 1, and the human coronavirus 229E. Apart from these antiviral actions, chloroquine is possesses immunomodulatory activity, suppressing the synthesis and release of interleukin-6 and tumour necrosis factor.

To test Savarino\'s hypothesis that the antimalarial chloroquine might in addition be active against SARS-CoV, an in vitro investigation was undertaken. This tested the ability of chloroquine to protect cell cultures infection by SARS-CoV.

Vero cell cultures were used to test the antiviral efficacy of chloroquine at the following concentrations: 0, 2, 4, 8, 16, 32, 64, 128, and 256 μM. Interferon was used as a positive control. One hundred times the infectious dose of SARS-CoV required to infect 50% of cell cultures was added to each culture at each of the chloroquine concentrations under test. Viral replication was measured by means of a real time reverse transcriptase polymerase chain reaction (RT-PCR) based assay, measured on supernatant from cell cultures. Cytotoxicity was assessed in parallel with inhibition of viral reproduction.

Culture supernatant assays showed that no significant viral replication occurred on day 1 of study at a chloroquine concentration of 4 μM. Activity declined with increasing time of incubation, with a 16 μM chloroquine concentration being required to effect 99% inhibition of viral replication on day 3 of study.

The study further examined the antiviral efficacy of chloroquine at the time of cell culture infection, and one hour post infection. Chloroquine proved equally effective when added at both time points; beyond that gradual loss of efficacy was observed with increasing interval between cell culture infection and the addition of chloroquine.

Overall, the concentration of chloroquine required to inhibit viral induced cytopathy by 50% (IC~50~) in vitro was found to be 8.8 μM, a level lower than that achieved with chloroquine therapy of acute malaria (25 mg/Kg); chloroquine treatment of rheumatoid arthritis (3.6 mg/Kg) yields plasma concentrations of 1--3 μM, within the same order of magnitude as the IC~50~ against SARS-CoV.

The authors conclude, given their results and chloroquine\'s cheapness, that it should be considered for "immediate use in the prevention and treatment of SARS-CoV infections".

*Biochem Biophys Res Comm. 2004; 323: 264--268*.

3. Comeback for chloroquine?
============================

3.1. Efficacy of antimalarial chemoprophylaxis among French residents travelling to Africa
------------------------------------------------------------------------------------------

This study, set in a Parisian travel clinic, compared the efficacy of chemoprophylaxis in French travellers to two different regions of Africa. Travellers presenting to the travel clinic within sixty days of return from a malarious area were eligible for inclusion. Enrolled travellers were asked to complete comprehensive questionnaires that examined compliance with anti-malaria recommendations, travel history, and socio-demographic factors. Travellers who proved positive for falciparum malaria were then classified as 'cases', falciparum negative travellers were classified 'controls'.

Countries visited were classified as belonging to either "Zone 2" or "Zone 3" in accordance with French practice. These zones are considered respectively to exhibit low and high chloroquine resistance. Patients who had visited French "Zone 1" countries, those without chloroquine resistance, were excluded from further study. Zone 2 includes: Burkina Faso, Chad, Gambia, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Madagascar, Mali, Mauritania, Namibia, Niger, Senegal, Sierra Leone, and Somalia. French expert chemoprophylaxis recommendations are for the use of chloroquine-proguanil (or mefloquine) in Zone 2, and mefloquine in Zone 3. Atovaquone-proguanil was not available during the course of this study.

Subjects were examined to determine whether they had taken chemoprophylaxis in accord with French expert recommendations for their destinations, and whether they had been compliant. Compliance was assessed from answers to questionnaires and blood levels of antimalarials and their metabolites.

From a total of 477 eligible for study, 289 were available for study: 131 with smears positive (cases) and 158 with smears negative(controls) for *Plasmodium falciparum*. Commonest final diagnoses for controls were "viral syndrome" and "intestinal infections". Cases differed from controls in presenting later after their return from abroad: median 10 versus 7 days (*P*\<0.001). Median duration of fever prior to presentation was the same for both groups, 4 days. Comparing the two groups further, cases were more likely to be of African ethnic origin, (*P*\<0.001) and to have visited West Africa (*P*\<0.001).

Further analysis revealed Ivory Coast to be a particularly high risk destination (OR=5.34, 95% CI: 2.28--12.5), while travelling with an organized tour reduced the risk of malaria (OR=0.11, 95% CI: 0.04--0.34). Use of (OR=0.42, 95% CI: 0.2--0.79) and compliance with (OR=0.21, 95% CI: 0.09--0.47) chemoprophylaxis in accord with French recommendations also reduced the malaria risk.

Of interest, chloroquine-proguanil exhibited an overall protective efficacy of 58% (95% CI: 22--78%) in Zone 2 countries, and mefloquine 90% (95% CI: 51--98%) in Zone 3. When efficacy was adjusted for compliance, the efficacy of chloroquine-proguanil in Zone 2 increased to 100% (95% CI: 89--100%), as did mefloquine\'s (95% CI: 58--100%) in Zone 3. Overall though, only 33% of travellers to Zone 2 and 11% of travellers to Zone 3 had taken adequate chemoprophylaxis.

The authors note that the level of adequate chemoprophylaxis use in French travellers is disappointing, attributing this to poor medical advice. The levels of compliance reported are lower than those reported in many other studies, a fact possibly explained by the high percentage of African travellers visiting friends and relatives. The authors speculate that the stricter criteria defining compliance in their study might also help explain this result. In defense of their criteria, they cite the fact that 90% of travellers judged compliant by their questionnaire answers demonstrated adequate blood antimalarial levels.

The final conclusion is that chloroquine-proguanil, taken correctly, remains highly efficacious in most West African countries, and can be recommended as chemoprophylaxis for travel to this region. In Zone 3 countries, the authors recommend mefloquine or atovaquone-proguanil.

*Trans R Soc Trop Med Hyg. 2004; 99: 91--100*

4. Is the bank safe?
====================

4.1. Assessing water-related risk factors for Buruli ulcer: a case-control study in Ghana
-----------------------------------------------------------------------------------------

Caused by infection with *Mycobacterium ulcerans*, Buruli ulcer is a disfiguring and disabling disease. Known geographic distribution incorporates at least 27 known countries in Africa, Asia, South America and the western Pacific. While previous studies have implicated proximity to environmental water as a risk factor, this study sought to identify specific epidemiological risk factors associated with environmental water.

Subjects were patients with Ziehl--Neelsen and polymerase chain reaction positive diagnoses of Buruli ulcer presenting for treatment at a mission hospital in rural Ghana. Fifty one subjects were available for study, and were compared with controls drawn from non-Buruli ulcer patients at the same hospital, matched for district of residence. Search for epidemiological risk factors was by means of a questionnaire, completed by investigators in the local language.

As previously reported elsewhere, the majority (67%, 34/51) of cases were in children aged \<15 years. A gender difference was observed in cases ≧15 years, with males predominating (*P*=0.003); 76% (36/51) of cases were recurrences.

Potential risk areas assessed by bivariate analysis were: type of water source utilized by victims, water related behaviors, the occurrence of cases within the family, and agricultural occupation. Of all of these, statistically significant associations were found only for use of rivers as a water source (OR=2.38, CI: 1.15--5.90, P=0.049), and for 'swimming' in rivers (OR=18, 95% CI: 3.77--362.13, P\<0.001). Of interest was the fact that agricultural work was not significantly associated with development of Buruli ulcer. Refinement of investigation by logistic regression revealed 'swimming' in rivers to be the sole significant risk factor.

The definition of swimming used in this study included play, exercise, fishing, laundering, fetching of water, and bathing. Thus exposure to river water seemed to be the actual risk factor. The authors point out, however, that previous results have demonstrated the wearing of long trousers to be protective against Buruli ulcer; another study suggested that wearing footwear might be protective, although that finding did not reach statistical significance. Bearing these other findings in mind, and the suggestion by other authors that *M. ulcerans* might be insect vectored, the authors postulate that resting on river banks after immersion in river water might be the actual risk factor, rather than the immersion itself, and call for further research to clarify this.

*Am J Trop Med Hyg. 2004; 71: 387--392*

5. Fishing for worms
====================

5.1. Treatment of cutaneous gnathostomiasis with ivermectin
-----------------------------------------------------------

Gnathostomiasis, caused by the migration of Gnathostoma roundworm larvae in humans, may be contracted through ingestion of raw or undercooked freshwater fish, snakes, chicken, frog, and other intermediate hosts. Cutaneous contact with the flesh of intermediate hosts may also possibly transmit infection. Usually the infection manifests as a migratory cutaneous swelling associated with an eosinophilia. Confined to the skin, larval migration may not be terribly serious; migration of larvae to the eye or central nervous system is however serious and potentially fatal.

Pharmacotherapy of gnathostomiasis has proven difficult, with treatment traditionally having relied upon surgical removal of the worms; this study compared the effectiveness of 21 days of albendazole, at 400 mg twice daily, with a stat 200 μg dose of ivermectin.

Strict diagnostic criteria were applied to potential subjects, with cutaneous gnathostomiasis diagnosed only if subjects had displayed migratory swellings of at least two days duration, an absolute eosinophilia \>500/mm^3^, their stools were negative for other parasites, and they had a positive Western blot specific for *G. spinigerum*. Additionally, subjects were required to have either a positive history of having eaten raw freshwater fish, crab, snake, bird, or chicken, or to have a positive cutaneous sensitivity test.

A total of 31 subjects were recruited, with seventeen randomly assigned to receive ivermectin, and 14 albendazole. The two groups showed no differences with respect to age, gender, and symptom history. Subjects were assessed clinically and by means of serology and blood counts before therapy, and then on days 14, 30, 60, 90, and 120. Clinical response was defined as the complete disappearance of all signs and symptoms and the normalization of the eosinophil count by day 60. Treatment was well tolerated in both groups.

Of the seventeen subjects administered ivermectin, thirteen (76.5%) demonstrated clinical response as per the above definition. The four failures were all retreated with 200 μg of ivermectin per day for two days. Of these four subjects, one initially developed a new cutaneous lesion upon retreatment, but all four cleared their skin lesions within three days, demonstrating a clinical response. Lesion clearance in this group took between 3 and 40 days (mean=6 days, mode=3 days). Ten of the 17 (58.8%) in this group demonstrated local skin reactions following treatment, including flares at known worms sites, and pruritis at other sites.

In the albendazole group, the clinical response rate was 92.8% (13/14). In the case which showed initial clinical failure a persistent lesion was biopsied. This revealed the presence of an immature adult *G. spinigerum*. Time to lesion clearance in this group ranged from 3 to 30 days and was not significantly different to the ivermectin group. Four out of the 14 in this group displayed local skin reactions; this was not significantly different to the rate in the ivermectin group.

Eosinophil counts in both groups decreased to normal by day 30 of the study. The authors report that anti-Gnathostoma serology declined equally slowly in both groups after treatment. Of interest, the appearance of local skin reactions in subjects showed no correlation with clinical outcome in either group. The authors do caution however that these reactions may theoretically exacerbate inflammation around eye or brain larvae, and care should be exercised to exclude occult infections.

There was no statistically significant difference in the clinical response rate between the two groups, and the authors conclude that ivermectin could be a reasonable alternative to albendazole for the pharmacotherapy of gnathostomiasis. The 100% clearance of lesions in the ivermectin group following retreatment might indicate that the initial dose should be higher.

*J Trop Med Hyg. 2004; 71: 623--628*

6. Thinking of Q
================

6.1. Q fever in travelers: 10 cases
-----------------------------------

This report from France details experience with Q fever in travellers, and is one of the largest series in the travel medicine literature. Despite the ubiquitous nature of the causative pathogen, *Coxiella burnetti*, Q fever is rarely diagnosed in travellers; it may be inferred from this report that the condition, at least in its less dramatic forms, my be underdiagnosed.

Of the 10 cases reported, 9 were male; ages ranged from 22 to 42 years. All had been in good health before contracting Q fever. Countries where the patient was thought to have contracted Q fever were: Bosnia (4), Chad (1), Congo (1), Mali (1), French Guyana (1), Tunisia (1), Reunion (1). Direct contact with farm animals was confirmed for 7 victims; wild or domestic rodents were suspected as the vectors in the remaining three cases.

Diagnosis was confirmed during the acute phase of disease in seven patients, and retrospectively in three others. Diagnosis was confirmed serologically in all cases, by means of direct immunoflourescence testing for antiphase II IgM or IgG antibodies against *C. burnetti*. All patients diagnosed with acute Q fever were febrile; five patients had lobar or segmental pneumonia diagnosed radiographically, with symptoms that included thoracic pain (3), cough (3), and the production of sputum (3). None of the confirmed pneumonia patients exhibited shortness of breath or other symptoms of severity; one had blood stained sputum from which a *Klebsiella pneumoniae* was cultured. The remaining patients demonstrated either jaundice or an influenza like syndrome.

The mean laboratory results upon admission were as follows: white cell count 6,470/mm^3^ (range 5,140--10,900/mm^3^), C-reactive protein 138 mg/L (range 20.4--198.0 mg/L). Deranged liver function indicative of cholestasis and hepatic cell injury were observed in 5 patients. There was no evidence of co-infection in any patient.

All patients were prescribed antibiotic treatment for 21 days, with one of the following: doxycycline, ciprofloxacin, pristinamycin (a streptogrammin in use in France), roxithromycin. Clinical and immunological follow up was for a minimum of 6 months. No complications or progress to chronic illness was observed in any patient.

The diagnosis in a French soldier who had bivouaced in a sheepfold provoked a serological survey amongst 24 other soldiers exposed to the same risk. Three of these were positive serologically; of these two had suffered a flu like illness of 3 days duration, while one gave no history of symptoms. All received 21 days of doxycycline to forestall the development of chronic disease. The authors recount outbreaks of Q fever amongst Czech troops stationed in Bosnia, and amongst troops who saw service in the Persian Gulf and other areas in the former Yugoslavia.

The point is made that the occurrence of mild cases, and the worldwide distribution of the pathogen, should prompt consideration of Q fever a as diagnosis in febrile travellers with a positive history of animal contact. More severe clinical syndromes including pneumonia and hepatitis should also prompt inclusion of Q fever in the differential diagnosis; splenic rupture attributable to Q fever has also been reported in travellers.

As serologic diagnosis may not be helpful, or may even be misleading, in the acute or early stages of the illness, treatment may need to be initially empirical. This should make use of antibiotics active intracellularly, such as doxycycline, for 21 days. The authors' review of the literature reveals a lack of clarity on the place of macrolides in the therapy of Q fever. Given the potential for chronicity and complications, follow up for one year is recommended.

*J Travel Med. 2004; 11: 383--385*

7. Atorvastatin and eggs
========================

7.1. Antischistosomal action of atorvastatin alone and concurrently with medroxyprogesterone acetate on *Schistosoma haematobium* harboured in hamster: surface ultrastructure and parasitological study
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Current schistosome control strategies rely heavily upon chemotherapy, with praziquantel being the sole agent deployed. This dependence upon a single molecule is problematic, having serious implications should resistance emerge, the latter being a concern in Egypt and Senegal. A search is accordingly being made for drugs which could either replace or complement praziquantel.

Hydroxy-methylglutaryl-coenzyme A (HMG-CoA) reductase is an enzyme present in both humans and schistosomes. In the former it regulates cholesterol biosynthesis, in the latter it regulates egg production. Other lipid lowering agents have shown the ability to block schistosome egg production, and to interfere with parasite protein glycosylation. Additionally, a few studies have indicated that steroid contraceptives might exert antischistosomal activity.

This study examined the effect of atorvastatin alone and in combination with the injected contraceptive medroxyprogesterone acetate (MPA), measuring the effect of these agents on egg production, worm load, and parasite tegument in a hamster model of *S. haematobium* infection.

Thirty female Syrian hamsters were randomly assigned to one of three groups of ten and infected subcutaneously by exposure to 180±10 *S. haematobium* cercariae. Group I received no treatment and acted as a control group; group II received intra-gastric atorvastatin (0.9 mg/Kg) for 49 consecutive days, commencing day 35 after infection; group III was administered MPA (0.1 mg/Kg) intramuscularly on days 7 and 35 post infection, but was otherwise identical to group II. Treatment scheduling was selected to mimic intervention timings in human disease.

All animals were sacrificed on day 84 of study, and examined for worm burden and sex in the liver and intestines; egg burden was similarly measured. An oogram expressing the percentages of eggs at various stages of maturation was also constructed for each group.

Worms from group II exhibited mild to severe alterations in their tegument. These changes were seen mainly in male worms, although a few female worms did exhibit some mild changes. Male worms in this group suffered shortening and rupture of tubercle spines, erosion and peeling of the tegument, and degeneration of sensory organelles; erosion of the oral sucker\'s dorsal tegument was also noted.

Tegumentary changes were also noted in worms from group III, principally again amongst males. Changes were not dissimilar to those in group II, but with the addition of exfoliation and exposure of underlying tissue. Additionally, oral suckers showed signs of severe injury.

Worm burden was reduced significantly (Student\'s *t*-test) in both groups II and III when compared with the control group, by 46.2% (*P*\<0.05) and 51.3% (*P*\<0.05), respectively. Egg burden in groups II and III was also reduced, from a mean of 9491 (SE±1811.8) in group I to 1000.3 (SE±215.4) in group II and 2014.8 (SE±495.2) in group III; reductions in both treatment groups were statistically significant (*P*\<0.05). There were no significant differences in egg and worm burden reductions between groups II and III, although the addition of MPA to atorvastatin resulted in an increased proportion of dead eggs in the oogram (*P*\<0.01)and a significant decrease in the percentage of immature ova (*P*\<0.05).

The authors note that the tegumentary changes observed were not dissimilar to those observed with praziquantel, artemether, astiban, and oxamniquine. They further speculate that the more severe damage exhibited in group III might indicate that some degree of recovery had commenced in group II worms. They conclude that further study is warranted to elucidate the mechanisms underlying the observed effects, and that atorvastatin and MPA may lead the way to the development of therapeutic strategies complementary to praziquantel.

*Acta Tropica. 2005; 93: 1--9*

8. Prophylaxis panic?
=====================

8.1. The risk of severe depression, psychosis, or panic attacks with prophylactic antimalarials
-----------------------------------------------------------------------------------------------

This study by the University of Basel utilized the United Kingdom\'s General Practice Research Database to examine whether mefloquine, given the anecdotal reports linking the drug to neuropsychiatric disturbance, really is associated with mental illness.

Subjects were aged between the ages of 17 and 79 years and had received between one and four prescriptions for mefloquine or chloroquine and/or proguanil, or a single prescription for doxycycline. The period studied extended through the decade ending 31 December 1999. Only prescriptions coded as issued for malaria prophylaxis were included in the study. Only subjects enrolled in the data base for at least 12 months were included. Subjects receiving the various antimalarials were then compared for the incidence of a first attack of the defined mental illnesses during drug use, within 90 days of drug use, and up to 18 months after drug use.

A total of 35,370 subjects were available for study; 16,491 had received mefloquine, 11,327 chloroquine-proguanil, 1217 proguanil alone, 3585 chloroquine alone, and 4574 doxycycline; some subjects received different antimalarials on different occasions. From the study population, 794 subjects with a possible diagnosis of psychosis, depression, or panic attack were identified, by reference to entries in their medical records reflected in the database. A blinded expert then excluded 214 subjects, due to lack of supporting evidence such as referral or prescription of a psychotropic agent. This left 580 subjects (68.8% female) with a diagnosis of depression, panic attack, or psychosis compatible with study criteria.

There was no statistically significant difference in the in the incidence of depression between users of any of the antimalarials. Smoking, age, and body mass index also showed no significant differences between the study groups, although smokers on any antimalarial medication were more likely to develop depression than non-smokers (OR 2.2, 95% CI: 1.7--2.9; *p*\<0.001).

Sixteen cases of psychosis were observed in the study overall. When the incidence in subjects currently taking was compared to all past users of antimalarials combined, the relative risk was 4.1 (95% CI: 1.1--15.0; *p*\<0.001); the actual risk was quantified for users as between 1 and 3 cases per 6700 treatment courses, described by the authors as low. Similarly, when the incidence of a first panic attack during mefloquine usage was compared with the incidence amongst all past users of antimalarials, the relative risk was 4.1 (95% CI: 1.9--8.6); the risk was higher for females (RR 2.0, 95%CI 1.1--3.6; *p*\<0.05).

The authors conclude that depression is not more common during or after mefloquine use. They believe their results do suggest though that first time diagnoses of acute psychosis and panic attacks may be more common during mefloquine use.

*Drug Safety. 2004. 27: 203--213*.
